كليدواژه :
مزالامين , سولفاسالازين , ulcerative colitis , Sulfasalasin , Mesalamin , كوليت اولسروز , پزشكي
چكيده لاتين :
Background and Objectives: Sulfasalasin (SAZ) is the main drug of choice for the treatment of ulcerative colitis (UC). Existing sulfafyridin in sulfasalasin is nost therapeutically effective, however it is responsible for 5 - Aminosalicylic acid transport and its side effect. Keeping the therapeutical effects of drug, sulfapyridin has been omitted from mesalamin (MZ) to omit its side effects. Regarding mesalaminʹs high cost , present study was conducted for the comparison of the effects and side effects of these two drugs in treating UC to clarify the cost - effectiveness of each drug.
Materials and Methods: A total fourty patients with UC, who had the same severity of disease on the basis of clinical, laboratory, endoscopic and histologic findings and based on scoring, were treated randomly with SAZ or MZ. They underwent clinical examination after 2 and 6 weeks of therapy, followed up by clinical and endoscopic examination after 3 months.
Results: Disease severity index in MZ group decreased from 15.1 (SD = 3.4) at admission time to 6.9 ( SD= 5.6) 3 months after therapy, and in SAZ group from 14.4 ( SD= 4.4 ) to 4.6 ( SD = 4.7 ), that is, both drugs caused improvement in the severity of disease ( p < 0.0001). However, the comparison of the response to drugs in two groups didnʹt show any significant difference ( p > 0.16). Few and mild side effects were observed in SAZ group .
Conclusion: Therapeutic response of sulfasalasin and mesalamin in the therapy of UC is the same, however sulfasalasinʹs side effects are few and mild.
